Ghosh S, Liu X P, Zheng Y, Uckun F M
Parker Hughes Cancer Center, St. Paul, MN 55113, USA.
Curr Cancer Drug Targets. 2001 Aug;1(2):129-40. doi: 10.2174/1568009013334188.
Increasing knowledge of the structure and function of the Epidermal Growth Factor Receptor (EGFR) subfamily of tyrosine kinases, and of their role in the initiation and progression of various cancers has led to the search for inhibitors of signaling molecules that may prove to be important in cancer therapy. The complex nature of EGFR biology allows for potential opportunities for EGFR inhibitors in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects. Different approaches have been used to target either the extracellular ligand-binding domain of the EGFR or the intracellular tyrosine kinase region that results in interference with its signaling pathways that modulate cancer-promoting responses. Examples of these include a number of monoclonal antibodies, immunotoxins and ligand-binding cytotoxic agents that target the extracellular ligand binding region of EGFR, and small molecule inhibitors that target the intracellular kinase domain and act by interfering with ATP binding to the receptor. During the past 3 years, significant progress has been made towards the identification of new structural classes of small molecule inhibitors that show high potency and specificity towards EGFR. The search for new small molecules that inhibit kinases has included traditional approaches like the testing of natural products, random screening of chemical libraries, the use of classical structure-activity-relationship studies, and the incorporation of structure-based drug design and combinatorial chemistry techniques. There has been a significant improvement in the development of selective EGFR inhibitors with the use of a structure-based design approach employing a homology model of the EGFR kinase domain. Molecular modeling procedures have been used to generate novel molecules that are complementary in shape and electrostatics to the EGFR kinase domain topography. This review focuses on some examples of the successful use of this method.
对表皮生长因子受体(EGFR)酪氨酸激酶亚家族的结构和功能,以及它们在各种癌症的发生和发展中所起作用的了解不断增加,促使人们寻找可能在癌症治疗中具有重要作用的信号分子抑制剂。EGFR生物学的复杂性为EGFR抑制剂在癌症治疗的多个领域提供了潜在机会,包括增殖、血管生成、侵袭和转移方面。已经采用了不同的方法来靶向EGFR的细胞外配体结合结构域或细胞内酪氨酸激酶区域,从而干扰其调节促癌反应的信号通路。这些方法的例子包括一些靶向EGFR细胞外配体结合区域的单克隆抗体、免疫毒素和配体结合细胞毒性剂,以及靶向细胞内激酶结构域并通过干扰ATP与受体结合而起作用的小分子抑制剂。在过去3年中,在鉴定对EGFR具有高效力和特异性的新型小分子抑制剂结构类别方面取得了重大进展。寻找抑制激酶的新小分子包括传统方法,如天然产物测试、化学文库随机筛选、经典构效关系研究的应用,以及基于结构的药物设计和组合化学技术的结合。通过使用基于EGFR激酶结构域同源模型的基于结构的设计方法,选择性EGFR抑制剂的开发有了显著改进。分子建模程序已被用于生成在形状和静电方面与EGFR激酶结构域拓扑互补的新型分子。本综述重点介绍了该方法成功应用的一些实例。